Odisha coronaviurs update: State sees fewer than 3,000 cases after 34 days

Odisha on Monday reported below 3,000 new Covid-19 cases after a gap of 34 days, even as the states coronavirus caseload went up to 2,35,330 with 2,617 new infections, an official said

Hospital, Coronavirus
Representative image
Press Trust of India Bhubaneswar
2 min read Last Updated : Oct 06 2020 | 7:04 AM IST

Odisha on Monday reported below 3,000 new COVID-19 cases after a gap of 34 days, even as the states coronavirus caseload went up to 2,35,330 with 2,617 new infections, an official said.

The state also registered 17 fresh fatalities pushing the death toll due to the disease to 924.

Odisha had reported 2,602 new positive cases on August 31, and from the next day onwards, it continued to detect more than 3,000 cases daily till October 4, he said.

On Monday, 2,617 people tested positive for COVID-19.

The state during the day also reported the recovery of 4,098 patients taking the total number of cured people to 2,06,400, which is 87.70 per cent of Odisha's caseload.

Of the new cases reported on Monday, 1,521 came from various quarantine centres and the rest were detected during contact tracing, he said.

Khurda district, of which state capital Bhubaneswar is a part, reported the maximum number of new cases at 506, followed by Bargarh at 148.

"Regret to inform the demise of seventeen #COVID-19 positive patients while under treatment in hospitals," the Health and Family Welfare Department said on Twitter.

Of the 17 fatalities, three each were registered in Cuttack and Puri districts, two each in Balasore, Boudh and Khurda and one each in Angul, Keonjhar, Nabarangpur, Rayagada and Sundargarh.

Fifty-three coronavirus patients have died due to comorbidities, according to the official.

Odisha currently has 27, 953 active cases.

As many as 34.82 lakh tests have been conducted so far, including 41,567 on Sunday.

With about 80 per cent of COVID-19 patients being treated in home isolation, the Odisha government to Monday decided to begin Favipiravir therapy for them.

Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate COVID-19 disease.

Chief Secretary A K Triptahy said that this therapy will save patients in home isolation from getting serious.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusOdisha Coronavirus Vaccine

First Published: Oct 06 2020 | 6:52 AM IST

Next Story